Uzansertib

Overview

Uzansertib (INCB053914) is an orally active, ATP-competitive pan- PIM kinase inhibitor with IC 50 s of 0.24 nM, 30 nM, 0.12 nM for PIM1 , PIM2 , PIM3 , respectively. Uzansertib has broad anti-proliferative activity against a variety of hematologic tumor cell lines.

Application

Products | Products > Disease Areas > Blood Disease | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Obesity | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Lipid Metabolism | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Signaling Pathways > JAK/STAT Signaling | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Pim

Product Information

• Catalog No.: HY-101870
• CAS No.: 1620012-39-6
• Molecular Formula: C26H26F3N5O3
• Molecular Weight: 513.51
• Purity: 99.45%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (4.87 mM); Clear solution
• Availability: In-stock

Source

Original product source